Bio Bridge Science (BGES) 8-K/A Completion of Acquisition or Disposition of Assets

Exhibit 99.2

 Bio-Bridge Science, Inc,

 Unaudited Pro Forma Condensed Consolidated Balance Sheet

 As of March 31, 2008

	Historical
	BGES			XHBD		Pro forma Adjustments			Notes		Pro forma Consolidated
Current Assets	(Unaudited)			(Unaudited)							(Unaudited)
Cash and cash equivalents	$	303,840		$	7,462	$					$	311,302
Accounts receivable					232,111							232,111
Inventories					508,601		302,556			c		811,157
Due from employees, net					15,684							15,684
Preaid expenses and other receivables		23,320			9,987							33,307
Other					652							652
Trading securities, at fair value		1,129,275					(854,823	)		b		274,452
Total Current Assets		1,456,435			774,497		(552,267	)				1,678,665
Fixed assets,net		63,132			148,285		54,994			c		266,411
Construction in progress		1,904,033										1,904,033
Land use right,net of current portion		376,861										376,861
Other					5,154							5,154
Intangible							410,656			c		410,656
TOTAL ASSETS	$	3,800,461		$	927,936	$	(86,617	)			$	4,641,780
CURRENT LIABILITIES
Accounts payables	$			$	636,888	$					$	636,888
Acccured expenses and other payables		157,215			17,226							174,441
Income taxes payable					53,343							53,343
Payable to vendor and contractors		129,064			49,864							178,928
Due to director or shareholder		28,494			777							29,271
Due to employees												—
Total Current Liabilities		314,773			758,098							1,072,871
LONG-TERM LIABILITIES
Defered tax liabilities		—			—							—
Total Long-term Liabilities		—			—							—
TOTAL LIABILITIES		314,773			758,098		—					1,072,871
MINORITY INTEREST		—			—		83,221			d		83,221
Shareholder Equity:
Preferred stock		4,000										4,000
Common stock/Momber's Equity		34,358			62,453		(62,455	)				34,358
Additional paid-in capital		10,592,165										10,592,165
Preferred stock dividend payable in common stock		47,000										47,000
Subscription receivable		(20,020	)									(20,020	)
Stock to be issued		257										257
Accumulated other comprehensive gain		308,474			12,968		(12,967	)				308,474
Accumulated decifit		(7,480,546	)		94,417		(94,416	)				(7,480,546	)
Total Shareholder's Equity		3,485,688			169,838		(169,838	)				3,485,688
TOTAL LIABILITIES AND SHREHOLDERS' EQUITY	$	3,800,461		$	927,936	$	(86,617	)			$	4,641,780

1

Bio-Bridge Science, Inc

Unaudited Pro Forma Condensed Consolidated Satements of Operations

For Three Months Ended March 31, 2008

							Pro forma					Pro forma
	Historical						Adjustments			Notes		Consolidated
	BGES			XHBD
Revenues	$	2,285		$	169,173		$					$	$171,458
Cost of goods sold		(891	)		(77,869	)		(46,721	)		e		(125,481	)
Gross Profit		1,394			91,304			(46,721	)				45,977
Research and development cost		36,533											36,533
Selling general and administrative expenses		218,890			35,940								254,830
INCOME(LOSS) FROM OPERATIONS		(254,029	)		55,364			(46,721	)				(245,386	)
Interest Income		26											26
Unrealized loss on trading securities		(70,862	)										(70,862	)
Loss on sale of trading securities		(9,766	)										(9,766	)
Dividend Income		46,117											46,117
Income (loss) before income taxes and minority interest		(288,514	)		55,364			(46,721	)				(279,871	)
Income Taxes					(13,841	)		11,680			f		(2,161	)
Minority Interest								(3,176	)		g		(3,176	)
NET INCOME (LOSS)		(288,514	)		41,523			(38,217	)				(285,208	)
Deemed Preferred Stock Dividends
Preferred Stock Dividends		(90,000	)		—								(90,000	)
Net Loss Attributable to Common Shareholders	$	(378,514	)	$	41,523		$	(38,217	)			$	(375,208	)
(Loss) Per Shares, baisc and diluted	$	(0.01	)	$	—							$	(0.01	)
Loss per share, attributable to common shareholders, basic and diluted	$	(0.01	)	$	—							$	(0.01	)
Weighted Average Share Outstanding, basic and diluted		34,357,676			34,357,676								34,357,676

2

Bio-Bridge Science, Inc

Unaudited Pro Forma Condensed Consolidated Satements of Operations

For The Year Ended Dcember 31, 2007

							Pro forma					Pro forma
	Historical						Adjustments			Notes		Consolidated
	BGES			XHBD
Revenues	$	2,979		$	550,764		$					$	$553,743
Cost of goods sold		(1,629	)		(351,225	)		(210,735	)		e		(563,589	)
Gross Profit (loss)		1,350			199,539			(210,735	)				9,846
Research and development cost		(155,087	)		—								(155,087	)
Selling expenses		(40,128	)		(13,396	)							(53,524	)
General and administrative expenses		(1,164,664	)		(84,499	)							(1,249,163	)
INCOME(LOSS) FROM OPERATIONS		(1,358,529	)		101,644			(210,735	)				(1,467,620	)
Interest Income		5,267											5,267
Unrealized loss on trading securities		(372,192	)										(372,192	)
Loss on sale of trading securities		(2,818	)										(2,818	)
Dividend Income		127,480											127,480
Income (loss) before income taxes and minority interest		(1,600,792	)		(101,644	)		(210,735	)				(1,709,883	)
Income Taxes					(35,709	)		35,709			f		—
Minority Interest								53,455			g		53,455
NET INCOME (LOSS)		(1,600,792	)		65,935			(121,571	)				(1,656,428	)
Deemed Preferred Stock Dividends		(1,293,320	)										(1,293,320	)
Preferred Stock Dividends		(317,000	)										(317,000	)
Net Loss Attributable to Common Shareholders		(3,211,112	)		65,935		$	(121,571	)				(3,266,748	)
Loss Per Shares, baisc and diluted	$	(0.05	)	$	—							$	(0.05	)
Loss per share, attributable to common shareholders, basic and diluted	$	(0.09	)	$	—							$	(0.10	)
Weighted Average Share Outstanding, basic and diluted		33,992,951			33,992,951								33,992,951

3

Notes:

a. The estimated purchase price has been preliminarily allocated based on estimated fair values of assets acquired and liabilities assumed in accordance with Statement of Financial Accounting Standards No. 141, “Business Combinations”. Upon the completion of the acquisition of HXBD, the Company will complete its valuation of the fair value of the acquired assets and liabilities; as such the allocation may change and result in amortizable intangibles. The Company’s preliminary purchase price allocation is as follows:

Cash	$	7,462
Accounts receivable		232,111
Inventories		811,157
Property and equipment		203,279
Other assets		31,477
Intangible		410,656
Accounts payable		(636,888	)
Accrued expenses		(17,226	)
Income taxes payable		(53,343	)
Minority interest		(83,221	)
Other payables		(50,641	)
Total purchase price	$	854,823

b. Reflects the acquisition of HXBD for $854,823 (RMB 6,000,000)

c. Reflects the increase in inventories and property and equipment based on preliminary allocation of estimated fair values.

d. Reflects the book value of minority interest

e. Reflects increase to cost of goods sold from increase in inventories

f. Reflects decrease to income tax due to higher cost of goods sold

g. Reflects minority interest income in pro-forma consolidation.

4